|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Symdeko
gptkb:CFTR_modulators
|
|
gptkbp:activities
|
potentiator of CFTR
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
January 31, 2012
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Kalydeco
|
|
gptkbp:class
|
gptkb:Cystic_fibrosis_transmembrane_conductance_regulator_(CFTR)_modulators
|
|
gptkbp:clinical_trial
|
Phase 3
approximately 50%
long-term treatment
VX-770-101
VX-770-102
VX-770-103
VX-770-104
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:discovered_by
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:dosage_form
|
tablets
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:formulation
|
film-coated tablets
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ivacaftor
|
|
gptkbp:indication
|
G551 D mutation in CFTR gene
|
|
gptkbp:ingredients
|
gptkb:Ivacaftor
C24 H28 Cl N3 O3 S
|
|
gptkbp:interacts_with
|
strong CY P3 A inducers
strong CY P3 A inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_used_for
|
gptkb:cystic_fibrosis
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
variable absorption
increases chloride transport
|
|
gptkbp:population
|
children and adults
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
Cystic Fibrosis Foundation guidelines
|
|
gptkbp:regulatory_compliance
|
gptkb:Health_Canada
gptkb:EMA
TGA
|
|
gptkbp:research_focus
|
gptkb:CFTR_modulators
|
|
gptkbp:rounds
|
urine
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
abdominal pain
diarrhea
rash
upper respiratory tract infection
liver function abnormalities
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
CFTR protein
|
|
gptkbp:type_of_care
|
important for efficacy
|